Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Research dashboard

Search approved medicines for AI-predicted activity against four drug-resistant pathogens, and see what evidence is already documented for each one.

TryTuberculosisMRSAKlebsiella infectionE. coli infection

1,761

Approved medicines

Approved medicines matched to the FDA Orange Book, antimicrobials included

1,276

Medicines with ≥40% AI-predicted activity

Against at least one of the four supported pathogens; each medicine counted once

1,019

Repurposing candidates

Of those, the medicines that are not already antimicrobials

How the repurposing candidates are counted

  1. 1,761approved medicines

  2. 1,276with AI-predicted activity ≥40% against at least one pathogen

    − 485 below ≥40%, not counted

  3. 1,120not already antimicrobials

    − 156 already antimicrobials, set aside

  4. 1,019repurposing candidates

    − 101 needing review, kept in the library

Existing antimicrobials are identified from WHO ATC codes and FDA pharmacologic classes. Medicines needing review (neither source says whether they are antimicrobials) stay in the approved-medicine download, marked “unclassified”. They are not assumed to be non-antimicrobials, so they are not counted as candidates.

Downloads

Download approved medicines (CSV)1,761 rowsDownload repurposing candidates (CSV)1,019 rows

Pathogen coverage

A medicine can count under more than one

Registered studies

A registration describes a study; it does not establish a positive result.

Condition
When these studies started38,873 of 39,548 have a start date · most in 2021 (1,903)
193119812030

  • Radiation-Free Technique for Evaluating Renal Scarring (RAFTERS)

    NCT03653702 · start 2027-07-01

    Registered record
    Registry ID
    NCT03653702
    Conditions
    Vesico-Ureteral Reflux
    Interventions
    Sulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2027-07-01
    Completion
    2029-07
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVesico-Ureteral Reflux
    InterventionSulfur Hexafluoride Lipid Type A Microspheres 25 MG Injection Powder for Suspension [LUMASON]
    PhasePhase 1
    Registry statusNot yet recruiting

  • Grain Moxibustion Treatment on Insomnia: a Randomized Controlled Trial

    NCT04980703 · start 2027-07-01

    Registered record
    Registry ID
    NCT04980703
    Conditions
    Sleep Initiation and Maintenance Disorders
    Interventions
    Grain moxibustion; Sham grain moxibustion; Standard care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2027-07-01
    Completion
    2029-07-31
    Enrolment
    102

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSleep Initiation and Maintenance Disorders
    InterventionGrain moxibustion; Sham grain moxibustion; Standard care
    PhaseNot applicable
    Registry statusNot yet recruiting

  • RSV Vaccination to Reduce Recurrent AECOPD

    NCT07508644 · start 2027-07-01

    Registered record
    Registry ID
    NCT07508644
    Conditions
    COPD; RSV
    Interventions
    RSV vaccination (Arexvy, GlaxoSmithKline)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2027-07-01
    Completion
    2030-12-31
    Enrolment
    320

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD; RSV
    InterventionRSV vaccination (Arexvy, GlaxoSmithKline)
    PhasePhase 4
    Registry statusNot yet recruiting

  • Na-Phenylbutyrate VAscular Trial

    NCT06645769 · start 2027-06-01

    Registered record
    Registry ID
    NCT06645769
    Conditions
    Diabetes
    Interventions
    Sodium Phenylbutyrate; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Not yet recruiting
    Start
    2027-06-01
    Completion
    2029-06-01
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDiabetes
    InterventionSodium Phenylbutyrate; Placebo
    PhaseEarly phase 1
    Registry statusNot yet recruiting

  • Pilot Studies Testing the Use of Oral Amitriptyline in Reducing Localized Burn Injury-induced Microvesicle Particle Release

    NCT07640061 · start 2027-06

    Registered record
    Registry ID
    NCT07640061
    Conditions
    Microvesicle Particles; Thermal Burn
    Interventions
    Amitriptyline; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2027-06
    Completion
    2033-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMicrovesicle Particles; Thermal Burn
    InterventionAmitriptyline; Placebo
    PhasePhase 1
    Registry statusNot yet recruiting

  • Risperidone vs Cariprazine in Acute Mania

    NCT07665073 · start 2027-06

    Registered record
    Registry ID
    NCT07665073
    Conditions
    Bipolar 1 Disorder
    Interventions
    Risperidone; Cariprazine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2027-06
    Completion
    2028-06
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBipolar 1 Disorder
    InterventionRisperidone; Cariprazine
    PhasePhase 4
    Registry statusNot yet recruiting

  • Chemo-embolization for Head and Neck Cancer

    NCT04595981 · start 2027-05

    Registered record
    Registry ID
    NCT04595981
    Conditions
    SCCHN; Squamous Cell Carcinoma
    Interventions
    Cisplatin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Withdrawn
    Start
    2027-05
    Completion
    2030-05
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSCCHN; Squamous Cell Carcinoma
    InterventionCisplatin
    PhasePhase 2
    Registry statusWithdrawn

  • Valproic AcId for Traumatic BRAin INjury Trial

    NCT07166393 · start 2027-05

    Registered record
    Registry ID
    NCT07166393
    Conditions
    Moderate Traumatic Brain Injury (TBI); Severe Traumatic Brain Injury
    Interventions
    Valproic Acid (VPA); Standard of care treatment + normal saline
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-05
    Completion
    2031-12
    Enrolment
    432

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionModerate Traumatic Brain Injury (TBI); Severe Traumatic Brain Injury
    InterventionValproic Acid (VPA); Standard of care treatment + normal saline
    PhasePhase 2 / Phase 3
    Registry statusNot yet recruiting

  • Observational Study of Raxibacumab in Sporadic Cases of Systemic Anthrax

    NCT07478471 · start 2027-05

    Registered record
    Registry ID
    NCT07478471
    Conditions
    Infections, Bacterial
    Interventions
    Collection of samples
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2027-05
    Completion
    2030-12
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfections, Bacterial
    InterventionCollection of samples
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

    NCT07437950 · start 2027-04-18

    Registered record
    Registry ID
    NCT07437950
    Conditions
    Acute Myeloid Leukemia
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Decitabine and Cedazuridine; Venetoclax
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2027-04-18
    Completion
    2034-09-22
    Enrolment
    126

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Decitabine and Cedazuridine; Venetoclax
    PhasePhase 2
    Registry statusRecruiting

  • Testing the Investigational Medication Combination of Teclistamab and Pomalidomide Compared to the Usual Treatment (Carfilzomib, Pomalidomide, and Dexamethasone) for Patients With Multiple Myeloma Who Have Relapsed Shortly After Treatment

    NCT07463807 · start 2027-04-12

    Registered record
    Registry ID
    NCT07463807
    Conditions
    Recurrent Multiple Myeloma; Refractory Multiple Myeloma
    Interventions
    Biospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Carfilzomib; Computed Tomography; Dexamethasone; FDG-Positron Emission Tomography; Fludeoxyglucose F-18; Pomalidomide; Teclistamab
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2027-04-12
    Completion
    2029-03-31
    Enrolment
    162

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRecurrent Multiple Myeloma; Refractory Multiple Myeloma
    InterventionBiospecimen Collection; Bone Marrow Aspiration; Bone Marrow Biopsy; Carfilzomib +6 more
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • Testing a Novel Combination Treatment (Arm D) Versus Standard of Care for Intensive Phase Treatment for Mycobacterium Abscessus Pulmonary Disease in People With or Without Cystic Fibrosis in the Finding the Optimal Regimen for Mycobacterium Abscessus Treatment (FORMaT) Adaptive Platform Trial

    NCT07485010 · start 2027-04

    Registered record
    Registry ID
    NCT07485010
    Conditions
    Mycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    Interventions
    Sulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin; clarithromycin; Clofazimine; Ethambutol; Amikacin Injection; tigecycline; Imipenem + Cilastatin; Cefoxitin; Amikacin (Inhalation); linezolid; Trimethoprim / Sulfamethoxazole; Doxycycline; moxifloxacin; bedaquiline; Rifabutin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2027-04
    Completion
    2031-07
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMycobacterium Abscessus Pulmonary Disease; Mycobacterium Abscessus Infection; Non-Tuberculous Mycobacterial (NTM) Infections; Non-Tuberculous Mycobacteria Pulmonary Disease
    InterventionSulbactam 25mg/kg -Durlobactam 25mg/kg (Every 6 hours); Ceftriaxone for Injection; Amoxicillin; Azithromcyin +14 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Impact of Hypoalbuminemia on Cefoperazone/Sulbactam Induced Coagulopathy in Post-Operative Surgical Patients

    NCT07773584 · start 2027-04

    Registered record
    Registry ID
    NCT07773584
    Conditions
    Cefoperazone/Sulbactam Induced Coagulopayjy
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2027-04
    Completion
    2027-10
    Enrolment
    108

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCefoperazone/Sulbactam Induced Coagulopayjy
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Double-blind, Randomized, Placebo-controlled Trial of Ganaxolone in CDKL5 Deficiency Patients 6 Months to Less Than 2 Years Old

    NCT05249556 · start 2027-03

    Registered record
    Registry ID
    NCT05249556
    Conditions
    CDKL5 Deficiency Disorder
    Interventions
    Ganaxolone; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-03
    Completion
    2029-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCDKL5 Deficiency Disorder
    InterventionGanaxolone; Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

  • Rct Assessing Pregnancy - Piroxicam for Ec With Levonorgestrel

    NCT07449299 · start 2027-03

    Registered record
    Registry ID
    NCT07449299
    Conditions
    Emergency Contraception; Contraception; COX-2 Inhibitor
    Interventions
    Levonorgestrel 1.5 mg and Piroxicam 40 mg; Oral LNG + Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Not yet recruiting
    Start
    2027-03
    Completion
    2031-11
    Enrolment
    1,458

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEmergency Contraception; Contraception; COX-2 Inhibitor
    InterventionLevonorgestrel 1.5 mg and Piroxicam 40 mg; Oral LNG + Placebo
    PhasePhase 3
    Registry statusNot yet recruiting

AI-predicted activity is a model’s estimate that a molecule is active against a pathogen in the laboratory. It is not clinical effectiveness. The models describe each pathogen species; the data behind them rarely records resistant strains.